Indian vaccine developer Bharat Biotech International Ltd is considering an initial public offering that may raise more than $500 million, according to people familiar with the matter. Deliberations ...

Type: Whole-virion, inactivated SARS-CoV-2 vaccine manufactured using a Vero Cell manufacturing platform and inactivated with alum as adjuvant 2021 Status: EUA REQUEST TO FDA—Ocugen said November 5 ...

This post was updated following a Bharat Biotech press conference today (Jan. 4). India’s drugs regulator has finally granted approvals to two Covid-19 vaccines, nearly a month after the drug makers ...

For the second time in five months, the FDA has put a clinical hold on Ocugen's application for Covaxin, its Bharat Biotech-partnered COVID-19 vaccine. (Ocugen) () In April of last year—soon after ...

MADISON, Wis.--(BUSINESS WIRE)--An international collaboration of virologists at the University of Wisconsin–Madison and the vaccine companies FluGen and Bharat Biotech has begun the development and ...

As the race to develop the world's first Chikungunya vaccine continues, two biotechs kicked off tests for their respective programs on Monday. Sponsored by the National Institutes of Health, Austria's ...